Immunome, Inc.
NASDAQ:IMNMBiotechnology
-$0.42 today
- Market cap
- $1.96B
- Beta
- 2.07
- P/E (TTM)
- -9.1
- EPS (TTM)
- -$1.99
Volume 0.88M
Average 1.23M
Returns on capital
Immunome, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-33.5%
avg -67.4%
ROIC
-33.5%
avg -134.2%
ROA
-31.1%
avg -105.7%
Analysis
ROA is currently the strongest return metric at -31.1% versus its period average of -105.7%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Clay Siegall | Chairman, President & Chief Executive Officer | USD 1.41M | 65 | — | — |
Max Rosett | Chief Financial Officer | USD 1.16M | 36 | 94.50K | 0.10% |
Jack Higgins | Chief Scientific Officer | USD 956.34K | 46 | 56.25K | 0.06% |
Robert J. Lechleider | Chief Medical Officer | USD 850.09K | 65 | — | — |
Sandra G. Stoneman | Chief Legal Officer, General Counsel & Corporate Secretary | USD 715.35K | 53 | 43.80K | 0.05% |
Kinney Horn | Chief Business Officer | USD 598.86K | 51 | 0 | <0.01% |
Roee Shahar | Executive Vice President of Commercial | — | — | — | — |
Philip Tsai | Chief Technical Officer | — | 58 | 76.50K | 0.08% |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Sep 11, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
11
$2.31M
Sells
28
$27.51M
Net Transaction Value
−$25.20M
Net selling
Most Active
Barchas Isaac
12 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Sep 11, 26Sep 11, 2026 | Higgins Jack Direct | Sell | $334.2K$334,224.00 |
| Aug 12, 26Aug 12, 2026 | Barchas Isaac Direct | Sell | $301.1K$301,058.00 |
| Aug 11, 26Aug 11, 2026 | Barchas Isaac Indirect | Sell | $1.6M$1,633,892.93 |
| Aug 10, 26Aug 10, 2026 | Barchas Isaac Indirect | Sell | $264K$263,958.75 |
| Aug 7, 26Aug 7, 2026 | Barchas Isaac Indirect | Sell | $397.4K$397,362.88 |
| Aug 6, 26Aug 6, 2026 | Barchas Isaac Indirect | Sell | $543.1K$543,090.40 |
| Aug 4, 26Aug 4, 2026 | Horn Kinney Direct | Sell | $2.3M$2,273,555.44 |
| Jul 7, 26Jul 7, 2026 | Barchas Isaac Indirect | Sell | $409.1K$409,125.20 |
| Jul 7, 26Jul 7, 2026 | Horn Kinney Direct | Sell | $27.3K$27,300.00 |
| Jul 6, 26Jul 6, 2026 | Barchas Isaac Indirect | Sell | $2M$2,003,396.34 |
1–10 of 39
Summary
Insiders reported 11 buys worth $2.31M and 28 sells worth $27.51M over the last 12 months. That adds up to net selling of $25.20M. Barchas Isaac was the most active insider with 12 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A3 analysts |
| Revenue | N/A | N/A | N/A | +141.6% (5yr)6 analysts |
| Net Income | N/A | N/A | N/A | N/A6 analysts |
| EBIT | N/A | N/A | N/A | N/A6 analysts |
Analysis
Forward estimates point to Revenue at +141.6% (5yr), giving you a quick read on expected growth from here.
Competitors
Who does Immunome, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about IMNM's management, answered from reported figures.
Who manages IMNM?
Immunome, Inc. (IMNM) lists 8 active executives. The top listed executive is Robert J. Lechleider, Chief Medical Officer.
Are IMNM insiders buying or selling?
Recent insider activity shows net buying of $77.67M.
Continue the stock analysis
Jump to another research area for this company.